Despite positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial opposition from pharmacy benefit managers. The organizations are https://gerardfgix498062.blogpixi.com/42369570/the-medication-faces-is-meeting-managed-care-organization-obstacles-a-look-of-reimbursement-battles